- KR₩62bn
- KR₩75bn
- KR₩141bn
Annual balance sheet for Yuyu Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 50,263 | 30,778 | 32,354 | 41,832 | 29,091 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 22,793 | 24,816 | 24,455 | 19,731 | 19,882 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 98,888 | 96,358 | 101,597 | 101,947 | 96,914 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 80,341 | 81,371 | 81,403 | 89,987 | 93,457 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 192,985 | 195,205 | 198,214 | 207,687 | 207,223 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 30,015 | 64,316 | 49,975 | 64,480 | 58,948 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 68,704 | 78,389 | 86,026 | 82,455 | 77,592 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 124,281 | 116,816 | 112,188 | 125,232 | 129,631 |
| Total Liabilities & Shareholders' Equity | 192,985 | 195,205 | 198,214 | 207,687 | 207,223 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |